Citadel Securities Maintains an 'Add' Biogen Idec (BIIB); Daclizumab May Add Leverage to Growing MS Franchise
Tweet Send to a Friend
Citadel Securities maintains an 'Add' Biogen Idec (NASDAQ: BIIB) price target of $130.00.
Citadel analyst said, "With early positive data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citadel analyst said, "With early positive data ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
